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Introduction 
Discoid lupus erythematosus (DLE) is the most pre-
valent manifestation of chronic cutaneous lupus 
erythematosus, other clinical manifestations are lupus 
profundus, lupus panniculitis, lupus tumidus, lupus 
erythematosus verrucosus and chilblain lupus[1]. 
There are no reliable evidence-based treatment 
recommendations available[2], but typical first-line 
treatment options consist of sun protection, topical 
corticosteroids, and antimalarial drugs; therapy-resis-
tant cases are usually treated with immunesuppressive 
drugs such as azathioprine, mycophenolate mofetil, 
or cyclophosphamide[1]. Depletion of CD20-positive 
B cells has been reported to be effective in systemic 
lupus erythematosus SLE[3-5], but two recent clinical 
trials did not show a positive effect of rituximab (anti-
CD20 antibody, RTX) in SLE[6, 7]. 
Here, we report a clinical response in a patient with 
a therapy-refractory  hypertrophic chronic discoid 
lupus erythematosus upon treatment with RTX. 
Case report
The then 22 year old patient was diagnosed in 1986 
with hypertrophic, partly verrucous form of DLE on 
the face, scalp, neck and the distal upper extremities. 
UV exposure led to worsening of the lesions. ANA 
(highest titer measured 1:320), anti-SSA (13), and anti-
SSB (1), as well as anti-dsDNA (5) and the normal C3 
and C4 values did never insinuate a development of a 
SLE. Accordingly, neither pathologic hematologic and 
urine tests nor clinical signs of systemic involvement 
were present at any time during the long observation 
period of the disease. 
The patient showed initially 
small plaques on face, scalp and 
arms, which, over time, became 
confluent and hypertrophic. Com-
pliance was believed to be insuffi-
cient, and neither nicotine abuse 
nor sun exposure during working 
hours as a mason was efficiently 
ceased or reduced. The biopsy 
showed interface dermatitis in as-
sociation with a pseudoepithelio-
matous hyperplasia of the epider-
mis, vacuolization of the junction 
zone and apoptotic keratinocytes. 
Focal mucin deposits were detec-
table in the alcian blue stain (fi-
gure 1).
Over the years, the patient was 
treated with topical steroids, hy-
droxychloroquine, prednisone in 
conjunction with azathioprine, 
isotretinoin or acitretin, systemic prednisone, my-
cophenolate mofetil, and radiotherapy on selected 
hypertrophic areas, but to no effect at all or no lasting 
effect. Based on reports in the literature [8], we trea-
ted the patient with efalizumab from February 2008 
till april 2009, when the drug was retracted from the 
market due to rare incidences of progressive multifo-
cal leukencephalopathy. During the first 4 months of 
efalizumab treatment (1mg/kg/week), the patient was 
weaned from systemic prednisone and mycopheno-
late mofetil. Erythema, scaling, and dermal induration 
improved, and the patient reported that his skin felt 
much less thickened and inflamed. Upon cessation 
of efalizumab, the symptoms rebounded, and he was 
put back on mycophenolate mofetil and prednisone. 
And intercurrent radiotherapy with anti-inflammatory 
dosage of 6x1Gy, 30kV on the lower arm did not im-
prove the dermatitis in the radiation field, and further 
irradiations were not pursued. 
The patient was included in a afamelanotide study 
(implantation of a synthetic analog of the naturally 
occurring alpha-melanocyte stimulating hormone 
(α-MSH) in june 2011, and august 2011), aiming at a 
reduced photosensitivity due to increased intrinsic 
melanin production, but again, there was no signifi-
cant clinical response to this experimental treatment. 
Due to the development of 2 squamous cell carcino-
ma on the penis and on the forearm, we were aiming 
at reducing the immunosuppression with prednisone 
and mycophenolate mofetil. In May 2013, the patient 
had a CLASI Total Activity/Total Damage Score of 
19/10, and we started with rituximab infusion accor-
ding to the rheumatologic infusion scheme (1000mg/
infusion on day 1 and day 15), and reduced predni-
sone/mycophenolate mofetil gradually. Upon the first 
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Fig. 1: Chronic discoid lupus erythematosus CDLE: 
A) pseudoepitheliomatous hyperplasia of the epidermis and interface derma-
titis with basal layer vacuolar changes, and apoptotic keratinocytes. Mononu-
clear (predominantly T cells) dermal inflammatory infiltrate. 
B) focal dermal mucine deposits in alcian blue stain. 
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infusion, inflammation of the involved skin was signi-
ficantly reduced and the patient reported much less 
scaling and redness (CLASI Score reduction to 10/10). 
Currently, the patient does not take any prednisone/
mycophenolate mofetilawaits the second infusion 
treatment upon recent and increase of peripheral 
CD19/20 positive B-cells. 
Discussion
Chronic discoid lupus erythematosus (chronic cuta-
neous lupus erythematosus, CDLE, CCLE) develop in 
approximately one fourth of SLE patients, but may also 
occur isolated [9]. Patients with isolated CDLE lesions 
usually have a negative or low antinuclear antibody 
(ANA) titer with rare increase of SSA/SSB antibodies 
[10]. Patients with extended cutaneous lesions and 
longer and therapy-refractory course of disease are at 
higher risk to develop SLE [11] [12]. As CDLE may be-
come hyperkeratotic, it may be confused with hyper-
trophic lichen ruber, prurigo nodularis, keratoacan-
thoma disseminatum, or even, at an early stage, with 
eczema or psoriasis. Histology at early stage is impor-
tant to differentiate between CDLE and other chronic 
dermatitis, as UV 
light should be 
avoided in the 
former, but is 
frequently used 
to treat the latter. 
Skin biopsy with 
direct immu-
nofluorescence 
(with detection 
of linear IgG, IgA, 
IgM, C1 and C3 
deposits, lupus-
band) in non-
s u n - e x p o s e d 
areas helps esta-
blishing the dia-
gnose. 
Given the photo-
sensitivity of the 
disease and the 
lack of large scale 
trials addressing 
the efficacy of 
sunscreens in the 
management of 
cutaneous lupus, 
patients should 
be advised to use 
broad spectrum, water-resistant suns-
creens with an SPF of at least 30, better 
50+. Beside the topical treatment with 
potent steroids, and calcineurin inhibitors 
in less active intervals, intralesional injec-
tion of triamcinolone crystal suspension 
has been described as an efficient local 
treatment in recurrent disease, but with 
low evidence[2]. First-line systemic treat-
ment consists in hydroxychloroquine 
which leads to a reduction HLA-DR+/
CD1a+ cells in lesional skin and reduced 
antigen presentation [13] [14]. In our pa-
tient, hydroxychloroquin (Plaquenil ®) did 
not show any effect, but the patient never 
ceased his nicotine abuse, which is belie-
ved to reduce efficiency of the drug [15] 
[16] by interfering with uptake of drug into cell lyso-
somes or an accelerated metabolic clearance of this 
medication. There is no randomized controlled clinical 
trial (RCT) data for the use of azathioprine, mycophe-
nolate mofetil (MMF), systemic cortisone for treatment 
of CDLE, and neither is there an RCT for efalizumab or 
any other biologic with T-cell inhibitory effect. When 
efalizumab was retracted from the market due to rare 
events of progressive multifocal leukencephalopa-
thy, we did not use any other antipsoriatic drug, as, in 
contrast to efalizumab, the TNF-blockers have been 
described to induce a lupus-like syndrome [17]. 
The anti-CD20 antibody rituximab has been appro-
ved in Switzerland for treatment of B-cell lymphoma, 
rheumatoid arthritis, and ANCA-associated vasculitis; 
however, it has been used for a series of dermatolo-
gic disorders, such as pemphigus vulgaris, bullous 
pemphigoid, dermatomyositis and lupus variants. In a 
recent review of the literature [18], RTX effect on cuta-
neous symptoms in cutaneous lupus, in a second line 
setting, was reported to be 80% complete response 
(8/10 patients), and 20% partial response (2/10 pa-
tients). Three patients developed a relapse within 12 
months, but their skin cleared again by an additional 
cycle of RTX [18]. 
Three patients 
suffered from SLE, 
whereas five pa-
tients had SCLE, 
and only one 
patient had CDLE 
(one patient not 
classified). Accor-
ding to the lite-
rature, it appears 
that B-cell deple-
tion is particularly 
beneficial in skin 
lesions of SLE, in 
SCLE, and to a les-
ser extent only in 
CDLE. It has been 
speculated that 
pathogenesis of 
CDLE may not be 
the same as in 
SLE, which may be 
mirrored in the in-
creased B-cell acti-
vity with increased 
ANA and antinu-
clear or anti-cyto-
plasmic antibodies 
Intercellular 
substance Nuclei 
Basal-
membrane 
Vessel 
wall 
Fibrinogen - - - - 
C3 - - + - 
IgG - - + - 
IgA - - - - 
IgM - - + - 
Table 1: Immunofluorescence microscopy of CDLE: Lupusband with 
linear Immunglobuline and C3 deposits along the basal membrane 
(cave: false positivity on sun-exposed skin and negative results in long-
standing chronic LE lesions)
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in SLE compared to CDLE [19]. 
The Cutaneous Lupus Erythematosus Disease Area 
and Severity Index (CLASI) was used to assess treat-
ment success. CLASI differentiates between disease 
activity and damage in 2 separate scores. The activity 
scale includes measurements of erythema, scale and 
hypertrophy in defined body regions, and mucous 
membrane disease, whereas the damage scale mea-
sures hyperpigmentation, atrophy, and scarring alo-
pecia in the same regions[20] [21]. This separation 
is unusual for dermatological scores, but useful for 
inflammatory disorders that may leave a permanent 
damage on the tissue, i.e. atrophy or scars. This dis-
tinction between activity and damage is established 
for the scoring of SLE. Our patient responded to the 
RTX treatment with a reduction of the inflammatory 
activity, but the inflicted damage of the decade-long 
course of disease could obviously not be reversed, 
hence the unchanged damage score. 
In summary, we report on a single case with the-
rapy-refractory chronic discoid lupus erythematosus 
withous systemic involvement who responded bene-
ficially towards a first cycle of rituximab infusion ac-
cording to the rheumatologic dosage of 2x1000mg in 
2 weeks interval. 
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Test 
Results [Highest/ 
lowest values] unit Reference values 
Rheuma factor <10 IE/ml <20 
ANA 1:320 Titer <1:10 
Anti-native DNS 18 IE/ml <20 
Anti-Chromatin 4 E/ml <20 
Anti-Histon 0.1 IE/ml <1.0 
Anti-SS-A 13 E/ml <5 
Anti-SS-B 1 E/ml <5 
Kompl. Factor C3c 1.30 g/l 0.90-1.80 
Kompl. Factor C4 0.35 g/l 0.10-0.40 
Immunkompl. C1q-Bdg. 1 % Bdg. <2 
Immunkompl. IgG 1 mg/l 1-10 
Anti Sm 0 E/ml <10 
Interleukine-6 5.7 pg/ml <3.1 
IgG 8.6 g/l 7.0-16 
IgM 0.6 g/l 0.4-2.3 
Table 2: Serological tests
